"A new plan to give away trade secrets could improve big pharma’s awful reputation,"writes Jim Giles in The Prospect. And the plan is being proposed by the new CEO of GlaxoSmithKline. Read more here.
Subscribe to:
Post Comments (Atom)
A blog about the intersection of medicine and business, produced by the members of the Medical Consumerism seminar at the University of Minnesota.
No comments:
Post a Comment